Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update Jun 30, 2025
Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference Jun 19, 2025
New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society May 28, 2025
Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025 May 26, 2025
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update May 13, 2025
Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results Apr 16, 2025
Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment Apr 8, 2025
Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment Mar 31, 2025
Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy Mar 20, 2025
Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook Feb 19, 2025
